1. Home
  2. CLPS vs GLTO Comparison

CLPS vs GLTO Comparison

Compare CLPS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

SELL

Current Price

$1.06

Market Cap

36.0M

Sector

Technology

ML Signal

SELL

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$30.06

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
GLTO
Founded
2005
2011
Country
Hong Kong
Denmark
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
1.8B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
CLPS
GLTO
Price
$1.06
$30.06
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$43.67
AVG Volume (30 Days)
14.8K
324.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
12.62%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$2.01
52 Week High
$1.88
$38.33

Technical Indicators

Market Signals
Indicator
CLPS
GLTO
Relative Strength Index (RSI) 48.17 55.96
Support Level $0.90 $3.32
Resistance Level $1.08 $32.63
Average True Range (ATR) 0.05 3.01
MACD -0.02 0.14
Stochastic Oscillator 13.33 70.93

Price Performance

Historical Comparison
CLPS
GLTO

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: